Kornimate/medical-research-clean huggingface dataset:
community partnership to examine racial and ethnic differences in health care for hypertension and diabetes

Conditions: Hypertension; Diabetes Mellitis

Summary: hypertension and diabetes are among the most common chronic diseases in the united states. racial and ethnic minority groups are more at risk for these diseases than the caucasian population. this study will attempt to identify factors that contribute to racial and ethnic differences in hypertension and diabetes care among minority patients of community health centers (chcs). this information will be used to design and implement programs to improve quality of care in these communities.

hypertension and diabetes are the primary contributors to today's high rates of heart disease and stroke, which are the first and third leading causes of death in the united states, respectively. african americans and hispanics have a higher risk of developing hypertension and diabetes than do caucasians. they are also less likely to know that they have high blood pressure, are more prone to organ damage, and are more likely to die as a result of these chronic conditions. a significant number of african americans and hispanics are uninsured and receive care through publicly supported chcs. it is important to identify factors that contribute to healthcare differences among the lower income, uninsured, and minority populations that are typically served by chcs. in this study, a collaborative partnership will be developed between chcs, health service research organizations, and academic researchers. the goal of the study is to examine the barriers that minority chc patients face in receiving appropriate hypertension and diabetes care. this study will develop a collaborative partnership between various health organizations and seven chcs located in boston neighborhoods that have a large percentage of african american and hispanic residents. researchers will conduct focus groups with chc patients who are receiving care for hypertension or diabetes. chc staff members will be interviewed to collect information regarding the relationship between chc organizational structure and disparities in heart disease risk factors among minority patients with hypertension or diabetes. researchers will then develop, implement, and evaluate a patient- and chc-focused intervention aimed at reducing the cardiovascular risks of minority patients at four chcs in boston.

Eligibility criteria:
inclusion criteria: * diabetes * hypertension, as diagnosed by the average of two or more blood pressure measurements taken during two or more study visits following an initial screening * race is 'black' or ethnicity is 'hispanic' * patient at participating community health center

Keywords: community health centers diabetes blood pressure, high
sentinel lymph node mapping in rectal cancer

Conditions: Rectal Neoplasms

Summary: the purpose of this study is to develop a technique that allows physicians to identify the first lymph nodes draining from a rectal tumor (the sentinel lymph nodes). currently, there is no technique used to find these lymph nodes in the rectum during surgery and therefore many patients with rectal cancer need to undergo a total rectal resection. dyes, tracers, imaging and a gamma probe will be used in this study during a standard minimally invasive transanal endoscopic surgery (tes) to try to locate these lymph nodes. if surgeons are able to locate these lymph nodes they will be removed during surgery. if the technique is successfully developed as a result of this research, it could help patients in the future with early stage rectal cancer by allowing doctors to see if their cancer has spread to the lymph nodes of the rectum without having to undergo a total rectal resection. these patients would then be able to undergo a tes combined with a lymph node dissection to gain more knowledge about the stage of their disease. this knowledge would then be used to determine if and what further treatment is necessary for the patient's rectal cancer.


Eligibility criteria:
inclusion criteria: * adult patients undergoing elective transanal endoscopic surgery (tes) at the university of virginia for rectal neoplasm (polyp with high grade dysplasia, t1n0 tumors \< 3cm in the absence of poor pathologic features, patients that refuse radical resection) * willing and able to give written informed consent exclusion criteria: * patients less than 18 years of age * women who are pregnant and/or breastfeeding * prisoners * unable to give written informed consent * patients with any of the following: * allergy to technetium, spot and/or icg * allergy to iodides * severe cardiac disease (hospitalization for cardiac disease in the last year, congestive heart failure, abnormal ekg) or renal disease (creatinine \> 2.0 mg/dl) * patients with medical contradictions or have potential problems complying with the requirements of the protocol, in the opinion of the investigator

Keywords: sentinel lymph node lymphatic mapping rectal tumor rectal cancer early stage
value of lng-ius as fertility-preserving treatment of eah and ec

Conditions: Endometrial Cancer; Atypical Endometrial Hyperplasia

Summary: primary end points: this clinical trial is aimed to analyze the effectiveness of levonorgestrel-releasing intrauterine system (lng-ius, mirena®) in the fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma, including pathology response and pregnancy outcome. second end points: to analyze the appearances of side-effects.


Eligibility criteria:
for patients with endometrial cancer： inclusion criteria: * ≤40 years of age: * having a strong desire for fertility preservation; * histological diagnosis is confirmed as well-differentiated (grade 1) endometrioid adenocarcinoma by the designated gynecological pathologists, and the progesterone receptors (pgrs) is positive in immunohistochemistry; * disease limited to the endometrium (stage 1a) on mri; * serum ca125/199 level is within normal limit (laparoscopic exploration to rule out ovarian tumor or another metastasis if necessary); * patients should have undergone counseling to learn fertility-preserving treatment is not standard of care for the treatment of ec, volunteered to participate in this study, signed the informed consent form, and agreed to participated in clinical follow-up. exclusion criteria: * patients have allergies or contraindications (except for thromboembolic disease, liver dysfunction, hypertension, and diabetes) for the involved drugs; * patients have lynch syndrome (ls); * patients have contraindications for pregnancy; * patients have serious underlying disease, malignancies at other site(s), acute liver or kidney disease, acute liver or kidney diseases, acute or subacute genital tract infections and congenital or acquired abnormal uterine development (that may make intrauterine device placement impossible); * patients refuse to participate in clinical follow-up or sign the informed consent form. for patients with endometrial atypical hyperplasia： inclusion criteria: * ≤ 40 years of age * having a strong desire for fertility preservation * histological diagnosis is confirmed as atypical endometrial hyperplasia (eah) by the designated gynecological pathologists * having volunteered to participate in this study, signed the informed consent form, and agreed to participate in clinical follow-up exclusion criteria: * patients have allergies or contraindications (except for thromboembolic disease, liver dysfunction, hypertension, and diabetes) for the involved drugs * patients have contraindications for pregnancy * patients have serious underlying disease, malignancies at other site(s), acute liver or kidney disease, acute or subacute genital tract infections, and congenital or acquired abnormal uterine development (that may make intrauterine device placement impossible) * patients refuse to participate in clinical follow-up or sign the informed consent form.
capsaicin for post-stroke dysphagia

Conditions: Dysphagia, Late Effect of Stroke

Summary: randomised, double blind, phase 2 trial to evaluate the efficacy of oral capsaicin in patients with post-stroke dysphagia in the (sub-)acute setting.

after inclusion and the assessment of the swallowing function (press, pas, fois, fees) patients will be randomised 1:1 to receive 1mcg capsaicin or placebo. oral treatment will be applied 3 times daily either during meals or during regular swallowing tests/trainings accompanied by a speech language pathologist. after re-assessment of the dysphagia after 7 days, patients with persistent dysphagia and applicable for further treatment will be treated for another 23 days with a final clinical swallowing evaluation after a total of 30 days. a patient medication diary will used during the duration of the trial to capture compliance.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke * impairment of oral intake with fois ≤ 4 * magnetic resonance imaging of the brain or ct scan with the finding of a subacute ischemic stroke * informed consent within 48 hours after admission, following initial swallowing assessment exclusion criteria: * diagnosis other than ischemic stroke * late patient admission \>48 hours after stroke onset * impairment of functional oral intake scale ≥ 5 * fees \>72h after admission * pas \<2 * pre-existing dysphagia * dysphagia due to other cause * no evidence of stroke on imaging * recurrent stroke = at least one stroke in the course of the study apart from the index stroke * age \<18 years * current drug abuse * amphetamine or amphetamine-like medication * regular oral treatment with chilli pepper extract * allergies or known adverse reactions to the consumption of chilli pepper or capsaicin * personality disorder * severe dementia or delirium * other reasons according to physician/investigator because of which the patient cannot participate in the study (not suitable for treatment or examinations) * withdrawal of consent by participant at any time of the study

Keywords: dysphagia stroke
acupuncture for chemotherapy-induced peripheral neuropathy

Conditions: Peripheral Neuropathy; Toxicity Due to Chemotherapy; Lymphoma; Multiple Myeloma

Summary: the purpose of this study is to evaluate whether acupuncture can be effective for chemotherapy-induced peripheral neuropathy in lymphoma or multiple myeloma patients.


Eligibility criteria:
inclusion criteria: * at least 18 years of age and have diagnosis of a lymphoma or multiple myeloma. * patients must have chemotherapy-induced peripheral neuropathy greater or equal to 2 according to ctcae (common terminology criteria for adverse events) v 3.0 scale (appendix a) in spite of previous conventional medications, e.g. neurontin, cymbalta and/or lyrica. patients receiving any of conventional medication for this symptoms must remain on the same medications throughout the study period. * patients, or the legal guardians of patients, must have the ability to understand korean, and be ble to provide informed consent. * ecog (eastern cooperative oncology group) performance status of 0, 1, or 2. * if the patient is a woman of child-bearing potential, she must have a negative urine pregnancy test and agree to use contraception. exclusion criteria: * other diseases that, in the opinion of the investigators, can cause peripheral neuropathy, such as alcoholism, diabetes mellitus, and hiv. * current active treatment for lymphoma or multiple myeloma * ongoing local infection at or near the acupuncture point adopted in this trial. * severe immunocompromised patients, leukopenia ( \< 4,000/㎣) or neutropenia ( \< 1,500/㎣) * known coagulopathy, thrombocytopenia (\< 50,000/㎣), and taking heparin (including low molecular weight heparin) or coumadin at any dose. * serious emotional or mental problems that precludes study entry. * mental and physical disability that precludes accurate acupuncture. * serious systemic diseases such as active infection, severe heart disease, uncontrolled hypertension and diabetes mellitus. * cardiac pacemaker. * pregnant or breastfeeding * acupuncture therapy within the previous 30 days * concurrent other complementary and alternative therapy such as herbal agents, high dose vitamins, and etc.

Keywords: acupuncture traditional korean medicine
a study to evaluate the efficacy and safety of multiple targeted therapies as treatments for participants with non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer

Summary: this is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in combination in participants with unresectable, advanced or metastatic nsclc determined to harbor oncogenic somatic mutations or positive by tumor mutational burden (tmb) assay as identified by a blood-based next-generation sequencing (ngs) circulating tumor dna (ctdna) assay.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of unresectable stage iiib not amenable to treatment with combined modality chemoradiation (advanced) or stage iv (metastatic) nsclc * eastern cooperative oncology group (ecog) performance status 0-2 * measurable disease * adequate recovery from most recent systemic or local treatment for cancer * adequate organ function * life expectancy greater than or equal to (\>/=) 12 weeks * for female participants of childbearing potential and male participants, willingness to use acceptable methods of contraception exclusion criteria: * inability to swallow oral medication * women who are pregnant or lactating * symptomatic, untreated cns metastases * history of malignancy other than nsclc within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or death * significant cardiovascular disease, such as new york heart association cardiac disease (class ii or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to randomization, unstable arrhythmias, or unstable angina * known active or uncontrolled human immunodeficiency virus (hiv) infection * either a concurrent condition or history of a prior condition that places the patient at unacceptable risk if he/she were treated with the study drug or confounds the ability to interpret data from the study * inability to comply with other requirements of the protocol
a phase 2a to evaluate the safety of medi8852 in adults with uncomplicated influenza

Conditions: Influenza

Summary: the purpose of this study is to evaluate safety and tolerability of a single dose of medi8852 when given with oseltamivir, the safety and tolerability of oseltamivir alone, and the safety and tolerability of a single dose of medi8852 alone in adult participants with acute, uncomplicated influenza caused by type a strains.

the medi8852 phase 2a study will evaluate the safety and tolerability of a single intravenous (iv) dose of medi8852 administered in conjunction with oseltamivir, the safety and tolerability of oseltamivir alone and the safety and tolerability of a single iv dose of medi8852 alone in adult participants with confirmed acute, uncomplicated influenza caused by type a strains. enrollment is planned in the united states, south africa, and australia.

Eligibility criteria:
inclusion criteria: * age 18 through 65 years at the time of screening. * symptomatic presumptive influenza a infection with onset of symptoms less than or equal to (≤) 5 days prior to medi8852 administration and defined as the presence of: * fever of greater than or equal to (≥) 38.0 degrees celsius (100.4 degrees fahrenheit) at screening and * ≥ 1 moderate systemic symptom (headache, malaise, myalgia, sweats and/or chills, or fatigue) and * ≥ 1 moderate respiratory symptom (cough, sore throat, or nasal symptoms) * influenza a infection confirmed with positive rapid antigen test * able to complete the follow-up period through day 101 as required by protocol (including telephone follow-up for days 11 to 101) * females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception for at least 2 days prior to the first dose of investigational product and must agree to continue using such precautions through day 101 of the study exclusion criteria: * hospitalized subjects. * receipt of influenza antiviral therapy within the preceding 14 days. * receipt of immunoglobulin or blood products within 6 months prior to screening. * known immunodeficiency due to illness, including human immunodeficiency virus (hiv), or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening. * current clinical evidence of pneumonia. * active bacterial infection requiring treatment with oral or parenteral antibiotics. * history of malignancy other than treated non-melanoma skin cancers or locally-treated cervical cancer in previous 3 years. * any planned surgical procedure before completion of day 101.

Keywords: influenza influenza a flu flu a
performance evaluation of a new daily disposable silicone hydrogel lens

Conditions: Myopia

Summary: the purpose of this study was to compare a new daily disposable, silicone hydrogel contact lens to marketed daily disposable, silicone hydrogel contact lenses.

part 1 of the study involved bilateral wear of three different types of marketed contact lenses. each type of lens was worn for three consecutive days of daily disposable wear. participants had been previously identified as symptomatic lens wearers or asymptomatic lens wearers, based upon their responses to a screening questionnaire. participants wore each lens type for as long as they were comfortable during the day, but lenses were removed before sleep. after completion of part 1, participants began part 2, which included dispensing of the investigational study lens for up to one week of bilateral wear, with a single follow-up visit at the end of that period.

Eligibility criteria:
inclusion criteria: * 17 years of age; full legal capacity to volunteer. * ocular examination within the last two years * correctable to a visual acuity of 20/30 or better (in each eye) with habitual vision correction. * currently wearing soft contact lenses. * clear corneas; no active ocular disease. * other protocol-defined inclusion criteria may apply. exclusion criteria: * currently wearing 1-day acuvue trueye or sauflon clariti 1-day contact lenses. * monovision. * any ocular disease. * never worn contact lenses before. * corneal refractive surgery. * uses topical ocular medicine. * other protocol-defined exclusion criteria may apply.
an efficacy and safety study of spx-101 inhalation solution in subjects with cystic fibrosis

Conditions: Cystic Fibrosis

Summary: 28-day double-blinded efficacy and safety trial of spx-101 inhalation solution in adult subjects with cystic fibrosis.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of cystic fibrosis * ppfev1 (percent predicted fev1) between 50.0% and 80.0% * stable cf lung disease * males and non-pregnant, non-lactating females exclusion criteria: * significant unstable co-morbidities within 28 days of screening * has received an investigational drug within 28 days of screening
high definition transcranial direct current stimulation (hd-tdcs) in patients with mild cognitive impairment

Conditions: Mild Cognitive Impairment

Summary: the study aimed to investigate whether high definition transcranial direct current stimulation (hd-tdcs) could benefit global cognitive function and sub-domains of cognition (visual/verbal/working memory, executive function, attention, processing speed, language, and frontal lobe function), mood (depression and anxiety), and subjective memory impairment in patients with mild cognitive impairment.

transcranial direct current stimulation (tdcs), a novel, non-invasive and safe neuro-modulating technique, has been developed as a new therapeutic option for neuropsychiatric disorders. it encompasses the induction of a relatively weak constant current flow through the cerebral cortex via scalp electrodes. dependent on stimulation polarity, this results in a modulation of cortical excitability and spontaneous neural activity. compared with tdcs, high-definition transcranial direct current stimulation (hd-tdcs) is highly focal and can specifically modulate cortical activity within the region confined by its 4 x 1 ring of elctrodes, such that the targeted region becomes more amenable to neuroplastic change. studies have suggested that tdcs improve cognition, including memory recall, verbal fluency and executive function. yet, there is not hd-tdcs study on mci. the purpose of this study is to examine whether hd-tdcs could benefit global cognitive function and sub-domains of cognition (visual/verbal/working memory, executive function, attention, processing speed, language, and frontal lobe function), mood (depression and anxiety), and subjective memory impairment in patients with mild cognitive impairment.

Eligibility criteria:
inclusion criteria: * aged 65 to 85 years * mild cognitive impairment * right handed exclusion criteria: * having epilepsy, severe physical illness, any current psychiatric comorbidity or history of substance dependence * having contraindications for transcranial electrical/magnetic stimulation. * having intracranial metal foreign bodies * having a history of intracranial neoplasms or surgery, or a history of severe head injuries or cerebrovascular diseases * receiving psychotropic agents such as antipsychotic, antidepressant, benzodiazepam and anxiolytics etc.